



## *Prototheca* spp. co-infections and their virulence factors in human protothecosis in Hillah city, Iraq

Manar R. Shanon<sup>a</sup>, Ali H. Al-Marzoqi<sup>b,\*</sup>, Hussein J. Hussein<sup>b</sup>

<sup>a</sup> College of Pharmacy, University of Babylon, Iraq

<sup>b</sup> College of Science for Women, Department of Biology, University of Babylon, Iraq

### ARTICLE INFO

#### Keywords:

Molecular diagnosis  
*Pseudomonas aeruginosa*  
*Prototheca* species  
Human protothecosis

### ABSTRACT

**Background:** The objective of the present study was to investigate coinfection of *Pseudomonas aeruginosa* and *Prototheca* species and other microorganisms in human protothecosis infections.

**Methods:** The current study included a collection of 275 clinical samples in Hillah, Iraq. Following bacterial identification, virulence factors genes were screened using polymerase chain reaction (PCR) technique.

**Results:** The results showed four types of *Prototheca* species *Prototheca zopfii* genotype1, *Prototheca zopfii* genotype2, *Prototheca stagnora* and *Prototheca blaschkeae* responsible for human protothecosis infections in burns, urinary tract infection (UTI), leukemia and dialysis. Furthermore, this study clarified coinfection of *Prototheca* spp. and *P. aeruginosa*. The predominant *Prototheca* spp. virulence genes included *lasR* (41.7%), *ecfXECF* (26.6%), *rhlR* (19.6%) and *toxAETA* (21.3%), with significant difference (P=0.047). Furthermore, there was an association between *Prototheca* spp. and *P. aeruginosa* virulence genes such as *PA-GS 16sRNA*, *lasB ELA520*, *toxAETA397*, *phzM PYO330*, *ecfXECF164*, *lasR*, *rhlR*, *PlcH*.

**Conclusion:** This study revealed the existence of *Prototheca* spp. carrying various virulence genes among burns and UTI in Hillah city, Iraq. Bacterial co-infections exacerbate the severity of infections, particularly those potential nosocomial pathogens. Identification of *P. aeruginosa* virulence genes among *Prototheca* spp. highlighted their role in severe infections.

### 1. Introduction

The *Prototheca* spp. are large non-budding organisms observed in tissue (Pore, 1985). It is spheroid, ovoid, or elliptical microorganism with a prominent wall, and the round cell (theca) contains several thick-walled Autospores. The genus *Prototheca* includes unicellular yeast-like, colorless microalgae (phylogenetically related to *Chlorella*), and its reproduction is asexual, and during cell maturation, the cytoplasm undergoes a process of cleavage to form endospores. After release from the maternal cell, these spores increase in size and undergo an assimilatory stage, more or less a pair of twenty endospores develop, initially in irregular form and therefore the sporangia break underneath the pressure of the increasing spores (Sudman and Kaplan, 1973), what's more, their number and size change among the *Prototheca* species (Padhye et al., 1979). Spore discharge happens each five to six hours visible of adequate supplements ample enhancements (Joshi et al., 1975).

Protothecosis is a zoonotic infection, as well as certain *Prototheca* species, e.g. *P. zopfii*, and *P. wicherhamii*, are human protothecosis etiological microalgae agents (Buzzini et al., 2004). Davies et al. (1964) firstly described the human infection of *Prototheca* species. *Pseudomonas aeruginosa* (*P. aeruginosa*) is the most important type of Gram negative bacteria that cause disease in human history because of various virulence factors such as a number of toxins, the production of extracellular enzymes as well as their resistance to phagocytosis (Laxmi and Sarita, 2014). Pathogenic *P. aeruginosa* is among substantial nosocomial agents in Iraq (Balaky et al., 2019; Ali et al., 2020; Al-Sa'ady et al., 2020; Husen, 2020). Then forming the biofilm in the position of infection, after they are collected in large numbers, and the membrane protects them from the defenses of the body and increases its resistance to antibiotics (Zubair et al., 2011; Fazeli and Momtaz, 2014). The first time record and was detected genetically for *Prototheca* species such as *P. zopfii* genotype 1, *P. zopfii* genotype 2, and *P. blaschkeae* in Iraq

**Abbreviations:** PCR, polymerase chain reaction; UTI, urinary tract infection; EDTA, ethylenediaminetetraacetic acid; TBE, tris borate EDTA; SDA, Sabouraud's dextrose agar; PIM, *Prototheca* isolation medium.

\* Corresponding author.

E-mail address: [almarzoqiali80@gmail.com](mailto:almarzoqiali80@gmail.com) (A.H. Al-Marzoqi).

<https://doi.org/10.1016/j.genrep.2020.101009>

Received 27 November 2020; Accepted 11 December 2020

Available online 19 December 2020

2452-0144/© 2020 Published by Elsevier Inc.

(Shanon et al., 2019). The current study was aimed to investigate coinfections of *P. aeruginosa* and *Prototheca* species in human protothecosis infections in Hillah city, Iraq.

## 2. Methods

### 2.1. Samples collection

The present study was extended for the period between September 2018 to March 2019 and included 275 patients with varying degrees of burns (82 patients), Urinary tract infection (UTI) (94 patients), Leukemia (46 patients), Dialysis (53 patients) group from Hillah General Teaching Hospital, lobby burns, Margan hospital, Iraq.

### 2.2. Isolation of bacterial species

*Prototheca* species were isolated using Sabouraud's dextrose agar (SDA) and selective media called *Prototheca* isolation medium (PIM) was prepared and incubated for 5–7 days at 25 °C according to (Pore, 1973), from a purified agar base with the addition of selective agents that inhibit bacterial growth and cultivate *Prototheca* (Pore, 1998; DiPersio, 2001; Roesler et al., 2006).

The following culture media were used according to the requirements growth of organisms. Nutrient agar medium to isolate, cultivate, and to save bacterial strains, MacConkey agar medium to isolate Gram-negative bacilli and to differentiate lactose fermented from non-lactose fermented bacteria. The API-20E platform was also performed to confirm the identified species. Blood agar medium was used to cultivate bacterial strains with ability of blood haemolysis. Additionally, mannitol salt agar was used to detect the growth of *Staphylococcus* species that have the ability of mannitol fermentation.

### 2.3. Polymerase chain reaction

In this study, eight primers (Ligo/USA) were used to detect diagnostic genes as shown in the Table 1.

Isolation of genomic DNA was performed using Promega Genomic DNA Purification Ki. Bacteria species genes were amplified using conventional polymerase chain reaction (PCR). The conditions of PCR for *P. aeruginosa* detection were as following: initial denaturation at 95 °C for 4 min followed by Denaturation at 95 °C for 1 min, annealing at 61 °C for 55 s and extension at 72 °C for 55 s continued for 40 cycles and thereafter, the final extension was at 72 °C for 8 min. The PCR reaction mixture for gradient consisted of 5 µL template DNA, 5 µL master mix, 5 µL of each forward and reverse primer reaching totally 20 µL reaction volume.

Ethical Approval: A valid consists was achieved from hospitals administration and from each patient before their inclusion in the study. For every patient or their followers, the procedure had been informed before the samples were collected, making absolutely sure that they understood the procedure. The subjects were sentient that they had the right to reject to be included in the study without any detrimental effects.

**Table 1**  
Sequence of primers used in this study.

Gene	Primers		Size (bp)	Reference	
	Forward	Reverse			
<i>lasB</i> ELA520	ACATCGCCCAACTGGTCTAC	ACCAGCGGATAGAACATGGT	520	(Shi et al., 2012)	
<i>tox</i> AETA397	ATGGTGTAGATCGGCGACAT	AAGCCTTCGACCTCTGGAAC	397		
<i>phzM</i> PYO330	CGGCGAAGACTTCTACAGCT	AGGTAGATATCGCCGTGGGA	330		
<i>ecf</i> XECF164	ATGCCTATCAGGCGTCCAT	GGCGATCTGGAAGAAATG	164		
<i>lasR</i>	ATCTTGTGGCTGACTGGAC	CTGCGGCAGTCTTTCGAGAAT	450		
<i>rhIR</i>	ACGGTCTGGCATAACAGATAGG	CCTCTCAGTCGGAGGACATACCA	900		
<i>PlcH</i>	GAAGCCATGGGCTACTTCAA	AGAGTGACGAGGAGCGGTAG	307		
<i>PA-GS</i> 16sRNA	GACGGGTGAGTAATGCCTA	CACCTGGTGTCTCTCTATA	599		
					(Köhler et al., 2010)
					(Ullah et al., 2017)
				(Ardura et al., 2013)	

## 3. Results

The study included the collection of 275 samples from different types of infections as follow: Burns (82 patients), UTI (94 patients), Leukemia (46 patients), Dialysis (53). The identification of *Prototheca* was done mainly based on the morphological characteristics of the organism on the affected loci or directly on the damaged tissue. We observed a typical appearance of the characteristic ovoid to globose sporangia with sporangiospores in several developmental stages (the so-called morula form). *Prototheca* species rate included 49 (32.2%) from burns, 53 (34.9%) from UTI, 22 (14.5%) from leukemia and 28 (18.4%) from dialysis. Accordingly, the highest ratio was detected in UTI (34.9%) followed by Burns (32.2%), Dialysis (18.4%) and Leukemia (14.5%) (Table 2).

The following results shows that *Prototheca* infections are always associated with *P. aeruginosa* infection, where note that the highest percentage of infection was *P. zopfii* genotype 1 (45%), followed by *Prototheca zopfii* genotype 2 (27.6%), and *P. blaschkeae* infection by (15.1%) and finally *P. stagnora* injuries by (11.8%), (Table 3). Through the results can also note that the highest infection of *P. zopfii* genotype 1, *P. zopfii* genotype 2, *P. stagnora* and *P. blaschkeae* were with *P. aeruginosa* by 19.1%, 15.1%, 7.2%, 9.2%, respectively. According to the statistical analysis of the results there was no significant relation regarding coinfections (p-value > 0.05). It is possible to attribute why *Prototheca* spp. infection is associated with *P. aeruginosa* as opportunistic organisms that exploit the rapid growth of bacteria as well as sharing the virulence factors. Other coinfection with *Prototheca* spp. included *Escherichia coli* (*E. coli*) (n = 33, 21.7%), *S. aureus* (n = 33, 15.1%), *Streptococcus pyogenes* (*S. pyogenes*) (n = 11, 7.2%) and *Acinetobacter baumannii* (*A. baumannii*) (n = 8, 5.3%).

The rate of virulence factors among *Prototheca* spp. has been represented in Table 4. Accordingly, *lasR*, *tox*AETA, *rhIR*, *ecf*XECF and *plcH* genes were predominant virulence genes in *Prototheca* spp. Other virulence factors included *PA-GS*, *16sRNA*, *lasB* ELA, and *phzM* PYO genes.

Among *Prototheca* spp., *P. zopfii* genotype 1, *P. zopfii* genotype 2, *P. stagnora* and *P. blaschkeae*, respectively mostly carried *lasR* (41.7%), *ecf*XECF164 (26.6%), *rhIR* (19.6%), *tox*AETA (21.3%) with significant difference (p = 0.047) (Table 4 and Fig. 1).

*LasR* gene and *rhIR* were identified by trademark band designs on 2% Agarose. The PCR items were 450 bp for *lasR* and 900 bp for *rhIR* as appeared in the accompanying (Fig. 2).

The PCR gel electrophoresis of *ToxAETA397*, *phzM* PYO330 and

**Table 2**  
Number and percentage of positive cases for *Prototheca* spp. growing on PIM and SDA with all cases including in this study.


Cases	No.	No. of positive	%
Burns	82	49	32.2
UTI	94	53	34.9
Leukemia	46	22	14.5
Dialysis	53	28	18.4
Total	275	152.0	100.0

**Table 3**The coinfection of *Prototheca* spp. with other nosocomial pathogens.

<i>Prototheca</i> spp.	<i>P. aeruginosa</i>		<i>E. coli</i>		<i>S. aureus</i>		<i>S. pyogenes</i>		<i>A. baumannii</i>		Total		p-Value
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	
<i>P. zopfii</i> genotype 1	29	19.1	15	9.9	13	8.6	7	4.6	5	3.3	69	45.4	>0.05
<i>P. zopfii</i> genotype 2	23	15.1	11	7.2	6	3.9	2	1.3	0	0.0	42	27.6	
<i>P. stagnora</i>	11	7.2	3	2.0	1	0.7	2	1.3	1	0.7	18	11.8	
<i>P. blaschkeae</i>	14	9.2	4	2.6	3	2.0	0	0.0	2	1.3	23	15.1	
Total	77	50.7	33	21.7	23	15.1	11	7.2	8	5.3	152.0	100.0	

**Table 4**Carriage of *P. aeruginosa* virulence genes by *Prototheca* spp. isolated from clinical samples.

Type of <i>Prototheca</i>	<i>P. aeruginosa</i> virulence genes														p-Value		
	<i>PA-GS 16sRNA</i>		<i>lasB ELA</i>		<i>toxAETA</i>		<i>phzM PYO</i>		<i>ecfXECF</i>		<i>lasR</i>		<i>rhIR</i>			<i>PlcH</i>	
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%		No.	%
<i>P. zopfii</i> genotype 1	29	24.8	21	31.8	24	32.0	22	37.9	20	31.3	20	41.7	18	39.1	16	38.1	0.047
<i>P. zopfii</i> genotype 2	23	19.7	14	21.2	16	21.3	11	19.0	17	26.6	12	25.0	9	19.6	11	26.2	
<i>P. stagnora</i>	11	9.4	8	12.1	11	14.7	6	10.3	7	10.9	5	10.4	9	19.6	3	7.1	
<i>P. blaschkeae</i>	14	12.0	12	18.2	16	21.3	10	17.2	7	10.9	6	12.5	8	17.4	4	9.5	
Non- <i>Prototheca</i> spp.	40	34.2	11	16.7	8	10.7	9	15.5	13	20.3	5	10.4	2	4.3	8	19.0	
Total	117	100	66	100	75	100	58	100	64	100	48	100	46	100	42	100	

**Fig. 1.** The electrophoresis of *lasB* gene in 5% NuSieve® 3:1 agarose gel in 1× TBE (Tris borate ethylene di-amide tetra acetic acid) buffer containing 5 µL red safe; L lane exhibits 100 bp DNA Ladder, well 1: negative control, well 2: positive control and wells 3–5: positive samples with 520 bp size.

*ecfXECF164* genes has been depicted in Fig. 3.

Moreover, the electrophoresis of the *PA-GS 16 s RNA* gene has been depicted in Fig. 4.

#### 4. Discussion


In this study, the *Prototheca* spp. were mostly isolated from UTI (n = 82, 49%) and burns (n = 94, 53%). *Prototheca* spp. have been isolated from infections. The rate of infections caused by *Prototheca* spp. has been different in various studies possibly due to sources of isolation, geographical or epidemiological differences, number of samples, the degree of hygiene and the type of sterilizers and disinfectants in the hospitals, as well as body neutrophils which play an important role in host defense against different species of *Prototheca*. *Prototheca* spp. are opportunistic pathogens which carry various virulence factors (Sari et al., 2018).

Our results revealed that *Prototheca* infections were associated with


*P. aeruginosa* infection, where the highest percentage of infection was regarding *P. zopfii* genotype 1 (45%), followed by *P. zopfii* genotype 2 (27.6%), and *P. blaschkeae* infection by (15.1%) and *P. stagnora* (11.8%). The coinfection of *P. zopfii* genotype 1, *P. zopfii* genotype 2, *P. stagnora* and *P. blaschkeae* were with *P. aeruginosa* included 19.1%, 15.1%, 7.2%, 9.2%, respectively. According to the statistical analysis of the results there was no significant relation regarding co-infections (p-value > 0.05). Other coinfections with *Prototheca* spp. included *E. coli* (n = 33, 21.7%), *S. aureus* (n = 33, 15.1%), *S. pyogenes* (n = 11, 7.2%) and *A. baumannii* (n = 8, 5.3%).

There are reports that patients with immunocompromised have neutrophils unable to kill *Prototheca* spp. (Phair et al., 1981; Sari et al., 2018).

Our results outlined that the *lasR*, *rhIR* and *plcH* genes were predominant virulence genes in *Prototheca* spp. Other virulence factors included *PA-GS*, *16sRNA*, *lasB*, *ELA520*, *toxAETA*, *phzM PYO* and *ecfXECF* genes. There is no previous data regarding *Prototheca* spp. rate



**Fig. 2.** The electrophoresis of *lasR* gene and *rhIR* products; well L: the 100 bp DNA Ladder, upper well 1: positive control, wells 2–4, 7, 8, 10, 11: *lasR* positive samples with 450 bp well 5: negative control, low wells 1 and 2: negative and positive control, respectively, 3–9: *rhIR* positive samples with 900 bp size.



**Fig. 3.** The electrophoresis of *toxA*, *phzM* and *ecfXECF* gene products; from right hand: L well the 100 bp DNA Ladder, wells 1 and 2: positive and negative control, respectively, wells 3–5: *tox A* gene positive samples with 397 bp size; Center: well 1 exhibits positive control and wells 2–6: positive samples with 330 bp size; Left: wells 1 and 2: negative and positive control respectively and wells 4–6: positive samples with 164 bp size.

and virulence factors in Iraq. Among *Prototheca* spp., *P. zopfii* genotype 1, *P. zopfii* genotype 2, *P. stagnora* and *P. blaschkeae*, respectively mostly carried *lasR* (41.7%), *ecfXECF164* (26.6%), *rhIR* (19.6%), *toxAETA* (21.3%) with significant difference ( $p = 0.047$ ). We suppose that *Prototheca* spp. infections are always associated with other pathogens, especially *P. aeruginosa* due to lethal agents, paving the way for the proliferation of *Prototheca* spp.

The *lasB* gene encodes one of substantial extracellular virulence factors, elastase classified as one of the proteolytic enzymes. *LasB* gene plays an essential function in the pathogenicity of *P. aeruginosa* through

host infection (Caiazza et al., 2005). The reason of increases its ferocity attributed to interaction with Proteins of the immune defense system, especially the multi-nuclei white blood cells, natural killer cells and IgA IgG immunoglobulins. Thus, strains of *P. aeruginosa*, which produce this enzyme, regulate the immune, making the body more susceptible to infection with other microorganisms such as *Prototheca* (Cotar et al., 2010). The *LasR* protein is a pivotal transcriptional activator of *P. aeruginosa* quorum sensing (QS) and plays a fundamental function in the activation of many virulence genes. Repeatedly *LasR* mutated, which helps to continuation bacterial infection and thus have severe clinical






Fig. 4. The electrophoresis of products; well L: 100 bp DNA marker, well 1: positive control, wells 2–6 and 8–10: positive samples with 307 bp.

effects (Smith et al., 2006). While, *rhIR* is a virulence factor playing an important role in the pathogenicity of *P. aeruginosa* (Jimenez et al., 2012).

*ToxAETA397* gene, *phzM* PYO330 gene and *ecfXECF164*: It can be described as the most deadly virulence factor and toxicity of the product by *P. aeruginosa*, which is considered a serious and often fatal inflammatory agent for the vast number of patients, the main function of this gene repression of protein synthesis, when it enters cytoplasm of eukaryotic cells through the protein part the molecular weight of 37 k Dalton, which works on the substance represented by of the elongation factor 2 which is in turn prevents elongation of the protein chain on the ribosome and eventual cell death (El-Zaim et al., 1998). It also has a practical role to grant tissues and reduce phagocytosis in people with severe burns (Pillar and Hobden, 2002). As for the *phzM* gene can be seen as an important virulence factor in *P. aeruginosa*, which is involved in the bio cyanine biosynthesis process, which plays an important role in inhibiting the growth of other microorganisms, as well as its negative impact on the phagocytic cells in patients (Wang et al., 2012). While *ecfX* gene considered is a kind of accurate diagnostic genes to *P. aeruginosa*, have extra cytoplasmic function encodes sigma factor which is restricted to *P. aeruginosa* as well might play major role in haem-uptake and the spread of bacteria in patients (Lavenir et al., 2007). The *plcH* gene is very important for *P. aeruginosa* playing a master role in hemolysis, interaction with host via protein secreted by type II secretion system, lipid catabolic process, pathogenesis and protein transport by the Tat complex (Hogan and Kolter, 2002). Identification of *P. aeruginosa* virulence genes among *Prototheca* spp. highlighted their role in severe infections.

## 5. Conclusion

This study revealed the existence of *Prototheca* spp. carrying various virulence genes mostly among burns and UTI in Hillah city, Iraq. Bacterial co-infections exacerbate the severity of infections, particularly those potential nosocomial pathogens. Identification of *P. aeruginosa* virulence genes such as *PA-GS 16sRNA*, *lasB ELA520*, *toxETA397*, *phzM* PYO330, *ecfXECF164*, *lasR*, *rhIR*, *PlcH* among *Prototheca* spp. highlighted their role in severe infections.

## Declaration of competing interest

This research has not been submitted for publication nor has it been published in whole or in part elsewhere. We attest to the fact that all authors listed on the title page have contributed significantly to the

work, have read the manuscript, attest to the validity and legitimacy of the data and its interpretation, and agree to its submission.

## Acknowledgements

This study was supported by University of Babylon. The study was edited by Dr. Abdolmajid Ghasemian.

## References

- Ali, F.A., Hussen, B.M., Zaki, S.M., 2020. Molecular detection of bla<sub>ctx-m</sub> gene among *Pseudomonas aeruginosa* strains isolated from different clinical samples in Erbil city. *Ann Trop Med Health* 23, 231.
- Al-Sa'ady, A.T., Mohammad, G.J., Hussen, B.M., 2020. Genetic relation and virulence factors of carbapenemase-producing Uropathogenic *Escherichia coli* from urinary tract infections in Iraq. *Gen Rep.* 21, 100911.
- Ardura, A., Linde, A., Garcia-Vazquez, E., 2013. Genetic detection of *Pseudomonas* spp. in commercial amazonian fish. *Int. J. Environ. Res. Public Health* 10 (9), 3954–3966.
- Balaky, S.T.J., Abdulkhalik, H., Hussen, B.M., Hassan, H., Mawlood, A.H., 2019. Molecular identification of *Acinetobacter baumannii* and *Acinetobacter genomic species 13TU* using PCR. *Zan J Pure Appl Sci* 31 (1), 17–22.
- Buzzini, P., Turchetti, B., Facelli, R., Baudino, R., Cavarero, F., Mattalia, L., Martini, A., 2004. First large-scale isolation of *Prototheca zopfii* from milk produced by dairy herds in Italy. *Mycopathologia* 158 (4), 427–430.
- Caiazza, N.C., Shanks, R.M., O'toole, G.A., 2005. Rhamnolipids modulate swarming motility patterns of *Pseudomonas aeruginosa*. *J. Bacteriol.* 187 (21), 7351–7361.
- Cotar, A.I., Chifiriuc, M.C., Dinu, S., Bucur, M., Iordache, C., Banu, O., Lazar, V., 2010. Screening of molecular virulence markers in *Staphylococcus aureus* and *Pseudomonas aeruginosa* strains isolated from clinical infections. *Int. J. Mol. Sci.* 11 (12), 5273–5291.
- Davies, R.R., Spencer, H., Wakelin, P.O., 1964. A case of human protothecosis. *Trans. R. Soc. Trop. Med. Hyg.* 58 (5), 448–451.
- DiPersio, J.R., 2001. *Prototheca* and protothecosis. *Clin. Microbiol. Newsl.* 23 (15), 115–120.
- El-Zaim, H.S., Chopra, A.K., Peterson, J.W., Vasil, M.L., Hegggers, J.P., 1998. Protection against exotoxin A (ETA) and *Pseudomonas aeruginosa* infection in mice with ETA-specific antipeptide antibodies. *Infect. Immun.* 66 (11), 5551–5554.
- Fazeli, N., Momtaz, H., 2014. Virulence gene profiles of multidrug-resistant *Pseudomonas aeruginosa* isolated from Iranian hospital infections. *Iran Red Crescent Med J* 16 (10).
- Hogan, D.A., Kolter, R., 2002. *Pseudomonas-Candida* interactions: an ecological role for virulence factors. *Science* 296 (5576), 2229–2232.
- Hussen, B.M., 2020. *Zanc. J Pur Appl Sci* 32 (4), 108–113.
- Jimenez, P.N., Koch, G., Thompson, J.A., Xavier, K.B., Cool, R.H., Quax, W.J., 2012. The multiple signaling systems regulating virulence in *Pseudomonas aeruginosa*. *Microbiol. Mol. Biol. Rev.* 76 (1), 46–65.
- Joshi, K.R., Gavin, J.B., Wheeler, E.E., 1975. The ultrastructure of *Prototheca wickerhamii*. *Mycopathologia* 56 (1), 9–13.
- Köhler, T., Guanella, R., Carlet, J., Van Delden, C., 2010. Quorum sensing-dependent virulence during *Pseudomonas aeruginosa* colonisation and pneumonia in mechanically ventilated patients. *Thorax* 65 (8), 703–710.
- Lavenir, R., Jocktane, D., Laurent, F., Nazaret, S., Cournoyer, B., 2007. Improved reliability of *Pseudomonas aeruginosa* PCR detection by the use of the species-specific *ecfX* gene target. *J. Microbiol. Methods* 70 (1), 20–29.
- Laxmi, M., Sarita, G., 2014. Reserch Article Diversity Characterization.

- Padhye, A.A., Baker, J.G., D'Amato, R.F., 1979. Rapid identification of *Prototheca* species by the API 20C system. *J. Clin. Microbiol.* 10 (4), 579–582.
- Phair, J.P., Williams, J.E., Bassaris, H.P., Zeiss, C.R., Morlock, B.A., 1981. Phagocytosis and algicidal activity of human polymorphonuclear neutrophils against *Prototheca wickerhamii*. *J. Infect. Dis.* 144 (1), 72–76.
- Pillar, C.M., Hobden, J.A., 2002. *Pseudomonas aeruginosa* exotoxin A and keratitis in mice. *Invest. Ophthalmol. Vis. Sci.* 43 (5), 1437–1444.
- Pore, R.S., 1973. Selective medium for the isolation of *Prototheca*. *Appl. Microbiol.* 26 (4), 648.
- Pore, R.S., 1985. *Prototheca* taxonomy. *Mycopathologia* 90 (3), 129–139.
- Pore, R.S., 1998. *Prototheca* and *Chlorella*. *Topley & Wilson's Microbiology and Microbial Infections* 4, 631–643.
- Roesler, U., Möller, A., Hensel, A., Baumann, D., Truyen, U., 2006. Diversity within the current algal species *Prototheca zopfii*: a proposal for two *Prototheca zopfii* genotypes and description of a novel species. *Prototheca blaschkeae* sp. nov. *International Journal of Systematic and Evolutionary Microbiology* 56 (6), 1419–1425.
- Sari, S., Dalgic, B., Muehlenbachs, A., DeLeon-Carnes, M., Goldsmith, C.S., Ekinci, O., Jain, D., Keating, M.K., Vilarinho, S., 2018 Jul 2. *Prototheca zopfii* colitis in inherited CARD9 deficiency. *J. Infect. Dis.* 218 (3), 485–489.
- Shanon, M. R., Hussein, Hussein J., & Al-Marzoqi, Ali H. (2019). Molecular identification and the first record of *Prototheca* Species from human Protothecosis in Iraq. *Biochemical and Cellular Archives*, 19 (Supplement 1): 2213–2218.
- Shi, H., Trinh, Q., Xu, W., Zhai, B., Luo, Y., Huang, K., 2012. A universal primer multiplex PCR method for typing of toxinogenic *Pseudomonas aeruginosa*. *Appl. Microbiol. Biotechnol.* 95 (6), 1579–1587.
- Smith, E.E., Buckley, D.G., Wu, Z., Saenphimmachak, C., Hoffman, L.R., D'Argenio, D.A., Burns, J.L., 2006. Genetic adaptation by *Pseudomonas aeruginosa* to the airways of cystic fibrosis patients. *Proc. Natl. Acad. Sci.* 103 (22), 8487–8492.
- Sudman, M.S., Kaplan, W., 1973. Identification of the *Prototheca* species by immunofluorescence. *Appl. Environ. Microbiol.* 25 (6), 981–990.
- Ullah, W., Qasim, M., Rahman, H., Jie, Y., Muhammad, N., 2017. Beta-lactamase-producing *Pseudomonas aeruginosa*: phenotypic characteristics and molecular identification of virulence genes. *Journal of the Chinese Medical Association* 80 (3), 173–177.
- Wang, C., Liu, L.L., Zhang, A.T., Xie, P., Lu, J.J., Zou, X.T., 2012. Antibacterial effects of zinc oxide nanoparticles on *Escherichia coli* K88. *Afr. J. Biotechnol.* 11 (44), 10248–10254.
- Zubair, M., Malik, A., Ahmad, J., Rizvi, M., Farooqui, K.J., Rizvi, M.W., 2011. A study of biofilm production by gram-negative organisms isolated from diabetic foot ulcer patients. *Biol Med* 3 (2), 147–157.